Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced that the US Food and Drug Administration (FDA) has designated Bronchitol as a fast-track product for cystic fibrosis.The FDA fast-tracks the New Drug Application (NDA) process if a therapy can potentially address an unmet medical need for a life-threatening disease. Designation as a fast- track product is designed to expedite regulatory review of the Bronchitol NDA. [click link for full article]
(more...)